title: Recent advances in the management of chronic heart failure.
abstract: OBJECTIVE
  This review will provide an overview of the recent advances in the management of chronic heart failure, with special focus on major publications in the past 2 years, 2010-2011.
  
  
  RESULTS
  In the past 1-2 years, there have been a number of publications that promise to make a major difference in patient management and outcome in heart failure. These include two clinical trials in patients with less symptomatic heart failure, namely the use of cardiac resynchronization therapy (CRT) and eplerinone, an aldosterone receptor antagonist, and another study using ivabradine, which belongs to a new class of If channel blocking drugs used for heart rate reduction in patients with moderate heart failure. The evolving role of telemedicine in remote management of patients with heart failure is reviewed.
  
  
  CONCLUSIONS
  New data demonstrate the benefit of CRT and aldosterone antagonists in milder heart failure, the benefit of ivabradine in moderate heart failure with heart rate of 70 or more, and the potential role of telemedicine.
authors.affiliation: Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. hhaddad@ottawaheart.ca
authors.forename: Haissam
authors.initials: H
authors.lastname: Haddad
authors.forename: Lisa
authors.initials: L
authors.lastname: Mielniczuk
authors.forename: Ross A
authors.initials: RA
authors.lastname: Davies
mesh_terms: D058406:Cardiac Resynchronization Therapy / Q000379:methods*; D002317:Cardiovascular Agents / Q000627:therapeutic use; D019468:Disease Management; D018450:Disease Progression; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D017216:Telemedicine / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D000451:Mineralocorticoid Receptor Antagonists